These vascular targeting agents were designed to bring soluble tissue factor (TF) to tumour endothelial cells by targeting MHC class II, cell adhesion molecules, fibronectin, or prostate specific membrane antigen, and then to cause the shutdown of the blood vessels of tumours by initiating blood clotting. Here, TF is linked to neoplasm.